Intraoperative molecular imaging: 3rd biennial clinical trials update

Patrick Bou-Samra; Najib Muhammad; Austin Chang; Ritesh Karsalia; Feredun Azari; Gregory Kennedy; Walter Stummer; Janos Tanyi; Linda Martin; Alexander Vahrmeijer; Barbara Smith; Eben Rosenthal; Patrick Wagner; David Rice; Amy Lee; Hafeez Abdelhafeez; Marcus M. Malek; Gary Kohanbash; Wilson Barry Edwards; Eric Henderson; Jane Skjøth-Rasmussen; Ryan Orosco; Summer Gibbs; Richard W. Farnam; Lalitha Shankar; Baran Sumer; Anand T. N. Kumar; Laura Marcu; Lei Li; Viktor Greuv; Edward J. Delikatny; John Y. K. Lee; Sunil Singhal

doi:10.1117/1.JBO.28.5.050901

13 May 2023 Intraoperative molecular imaging: 3rd biennial clinical trials update

Patrick Bou-Samra, Najib Muhammad, Austin Chang, Ritesh Karsalia, Feredun Azari, Gregory Kennedy, Walter Stummer, Janos Tanyi, Linda Martin, Alexander Vahrmeijer, Barbara Smith, Eben Rosenthal, Patrick Wagner, David Rice, Amy Lee, Hafeez Abdelhafeez, Marcus M. Malek, Gary Kohanbash, Wilson Barry Edwards, Eric Henderson, Jane Skjøth-Rasmussen, Ryan Orosco, Summer Gibbs, Richard W. Farnam, Lalitha Shankar, Baran Sumer, Anand T. N. Kumar, Laura Marcu, Lei Li, Viktor Greuv, Edward J. Delikatny, John Y. K. Lee, Sunil Singhal

Author Affiliations +

Journal of Biomedical Optics, Vol. 28, Issue 5, 050901 (May 2023). https://doi.org/10.1117/1.JBO.28.5.050901

Abstract

Significance

This third biennial intraoperative molecular imaging (IMI) conference shows how optical contrast agents have been applied to develop clinically significant endpoints that improve precision cancer surgery.

Aim

National and international experts on IMI presented ongoing clinical trials in cancer surgery and preclinical work. Previously known dyes (with broader applications), new dyes, novel nonfluorescence-based imaging techniques, pediatric dyes, and normal tissue dyes were discussed.

Approach

Principal investigators presenting at the Perelman School of Medicine Abramson Cancer Center’s third clinical trials update on IMI were selected to discuss their clinical trials and endpoints.

Results

Dyes that are FDA-approved or currently under clinical investigation in phase 1, 2, and 3 trials were discussed. Sections on how to move benchwork research to the bedside were also included. There was also a dedicated section for pediatric dyes and nonfluorescence-based dyes that have been newly developed.

Conclusions

IMI is a valuable adjunct in precision cancer surgery and has broad applications in multiple subspecialties. It has been reliably used to alter the surgical course of patients and in clinical decision making. There remain gaps in the utilization of IMI in certain subspecialties and potential for developing newer and improved dyes and imaging techniques.

CC BY: © The Authors. Published by SPIE under a Creative Commons Attribution 4.0 International License. Distribution or reproduction of this work in whole or in part requires full attribution of the original publication, including its DOI.

Citation Download Citation

Patrick Bou-Samra, Najib Muhammad, Austin Chang, Ritesh Karsalia, Feredun Azari, Gregory Kennedy, Walter Stummer, Janos Tanyi, Linda Martin, Alexander Vahrmeijer, Barbara Smith, Eben Rosenthal, Patrick Wagner, David Rice, Amy Lee, Hafeez Abdelhafeez, Marcus M. Malek, Gary Kohanbash, Wilson Barry Edwards, Eric Henderson, Jane Skjøth-Rasmussen, Ryan Orosco, Summer Gibbs, Richard W. Farnam, Lalitha Shankar, Baran Sumer, Anand T. N. Kumar, Laura Marcu, Lei Li, Viktor Greuv, Edward J. Delikatny, John Y. K. Lee, and Sunil Singhal "Intraoperative molecular imaging: 3rd biennial clinical trials update," Journal of Biomedical Optics 28(5), 050901 (13 May 2023). https://doi.org/10.1117/1.JBO.28.5.050901

Received: 3 March 2023; Accepted: 13 April 2023; Published: 13 May 2023

ACCESS THE FULL ARTICLE

JOURNAL ARTICLE
33 PAGES

DOWNLOAD PAPER SAVE TO MY LIBRARY